Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Molecular Profile | JAK3 M511I |
Therapy | Tofacitinib |
Indication/Tumor Type | T-cell acute lymphoblastic leukemia |
Response Type | sensitive |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
JAK3 M511I | T-cell acute lymphoblastic leukemia | sensitive | Tofacitinib | Preclinical - Patient cell culture | Actionable | In a preclinical study, Xeljanz (tofacitinib) treatment inhibited downstream signaling, induced apoptosis, and reduced cell viability of patient-derived T-cell acute lymphoblastic leukemia cell lines harboring JAK3 M511I (PMID: 35411095). | 35411095 |
PubMed Id | Reference Title | Details |
---|---|---|
(35411095) | JAK3 mutations and mitochondrial apoptosis resistance in T-cell acute lymphoblastic leukemia. | Full reference... |